PMX Inc., a South Korean startup focusing on AI-based diagnostic solutions, announced it had successfully attracted a Series-A investment. Since its foundation in early 2020, it has raised a total investment of 5 billion won ($4.2 million).
The round was led by Intervalue Partners, BNK Venture Investment, and Korea Alternative Investment for the Seoul-based firm that tries to tackle such diseases as Alzheimer’s and Parkinson’s.
PMX plan to use this funding to improve the performance of A technologies under development and complete US licensing.
Company: PMX Inc.
Raised: undisclosed amount
Round: Series A
Funding Month: December 2021
Lead Investors: Intervalue Partners, BNK Venture Investment, and Korea Alternative Investment
Company Website: https://www.pmx-inc.com/
Software Category: AI-based diagnostic solutions
About the Company: PMX is a digital health company that delivers personalized physical examination through the democratization of medical imaging with AI to providers and patients all around the world. In particular, the outfit has worked on AI-based solutions for early diagnose of Alzheimer’s and Parkinson’s diseases using CT and MRI scan images, including biomarkers. PMX has developed a multi-modality imaging platform to measure the major vital organs and tissues of the body for universal care and wellness. Currently, PMX operates offices in Seoul and Chicago, targeting the markets of South Korea and the United States. The Seoul office is its headquarters, while the Chicago branch is responsible for research, approval of the Food and Drug Administration, and distribution across the U.S.